Temporal aspects of the action of ASA404 (vadimezan; DMXAA)

By Baguley Bruce C   Siemann Dietmar W  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1413-1425

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA)

By Jameson Michael B   Head Michelle  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 10, 2011-10 ,pp. : 1315-1326

Informa Healthcare

Access to resources Recommend Favorite

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer

By McKeage Mark J  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 1, 2008-01 ,pp. : 23-29

Informa Healthcare

Access to resources Recommend Favorite

Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

By Zhao Liangli   Marshall Elaine   Kelland Lloyd   Baguley Bruce  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 271-276

Springer Publishing Company

Access to resources Recommend Favorite

Vascular-disrupting agents in oncology

By Mita Monica M   Sargsyan Liza   Mita Alain C   Spear Matt  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 3, 2013-03 ,pp. : 317-328

Informa Healthcare

Access to resources Recommend Favorite